IMDX
NASDAQ · Biotechnology
Insight Molecular Diagnostic
$7.32
+0.63 (+9.42%)
Open$6.73
Previous Close$6.69
Day High$7.48
Day Low$6.54
52W High$15.94
52W Low$11.01
Volume—
Avg Volume555.2K
Market Cap209.82M
P/E Ratio40.04
EPS$0.37
SectorBiotechnology
Analyst Ratings
Buy
10 analysts
Price Target
+137.8% upside
Current
$7.32
$7.32
Target
$17.41
$17.41
$14.05
$17.41 avg
$26.42
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.94M | 22.03M | 22.77M |
| Net Income | 4.47M | 4.29M | 5.70M |
| Profit Margin | 20.4% | 19.5% | 25.1% |
| EBITDA | 9.15M | 9.08M | 9.52M |
| Free Cash Flow | 3.10M | 3.08M | 2.32M |
| Rev Growth | -4.7% | +9.7% | +22.0% |
| Debt/Equity | 1.02 | 1.02 | 1.06 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |